Browse the corpus

REFERENCES Bronstein MD, “Prolactinomas and Pregnancy,” Pituitary , 2005, 8(1):31-8. [PubMed 16411066 ] European Multicentre Study Group for Cabergoline in Lactation Inhibition, “Single Dose Cabergoline Versus Bromocriptine in Inhibition of Puerperal Lactation: Randomised, Double-Blind, Multicentre Study,” BMJ , 1991, 302(6789):1367-71. Ferrari C, Paracchi A, Mattei AM, et al, “Cabergoline in the Long-Term Therapy of Hyperprolactinemic Disorders,” Acta Endocrinol (Copenh) , 1992, 126(6):489-94. [PubMed 1642081 ] Giusti M, Porcella E, Carraro A, et al, “A Cross-Over Study With the Two Novel Dopaminergic Drugs Cabergoline and Quinagolide in Hyperprolactinemic Patients,” J Endocrinol Invest , 1994, 17(1):51-7. [PubMed 7911813 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Rains CP, Bryson HM, and Fitton A, “Cabergoline: A Review of Its Pharmacological Properties and Therapeutic Potential in the Treatment of Hyperprolactinemia and Inhibition of Lactation,” Drugs , 1995, 49(2):255-79. [PubMed 7729332 ] Ricci E, Parazzini F, Motta T, et al, “Pregnancy Outcome After Cabergoline Treatment in Early Weeks of Gestation,” Reprod Toxicol , 2002, 16(6):791-3. [PubMed 12401507 ] Robert E, Musatti L, Piscitelli G, et al, “Pregnancy Outcome After Treatment With the Ergot Derivative, Cabergoline,” Reprod Toxicol , 1996, 10(4):333-7. [PubMed 8829257 ] Roth BL, “Drugs and Valvular Heart Disease,” N Engl J Med , 2007, 356(1):6-9. [PubMed 17202450 ] Schade R, Andersohn F, Suissa S, et al, “Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation,” N Engl J Med , 2007, 356(1):29-38. [PubMed 17202453 ] Webster J, Piscitelli G, Polli A, et al, “A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea,” N Engl J Med , 1994, 331(14):904-9. [PubMed 7915824 ] Webster J, Piscitelli G, Polli A, et al, “Dose-Dependent Suppression of Serum Prolactin by Cabergoline in Hyperprolactinaemia: A Placebo Controlled, Double Blind, Multicentre Study,” Clin Endocrinol (Oxf) , 1992, 37(6):534-41. [PubMed 1286524 ]

Webster J, Piscitelli G, Polli A, et al, “A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea,” N Engl J Med , 1994, 331(14):904-9. [PubMed 7915824 ] Webster J, Piscitelli G, Polli A, et al, “Dose-Dependent Suppression of Serum Prolactin by Cabergoline in Hyperprolactinaemia: A Placebo Controlled, Double Blind, Multicentre Study,” Clin Endocrinol (Oxf) , 1992, 37(6):534-41. [PubMed 1286524 ] Webster J, Piscitelli G, Polli A, et al, “The Efficacy and Tolerability of Long-Term Cabergoline Therapy in Hyperprolactinaemic Disorders: An Open, Uncontrolled, Multicentre Study,” Clin Endocrinol (Oxf) , 1993, 39(3):323-9. [PubMed 7900937 ] Zanettini R, Antonini A, Gatto G, et al, “Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease,” N Engl J Med 2007, 356(1):39-46. [PubMed 17202454 ] Topic 8600 Version 44.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]